Oppenheimer analyst Jay Olson reiterated a Perform rating on Editas Medicine (NASDAQ: EDIT).The analyst commented: "EDIT reported 3Q24 OpEx of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE